10 January 2026
1 min read

NAB share price slips as rate bets shift; key dates ahead for National Australia Bank stock

NAB share price slips as rate bets shift; key dates ahead for National Australia Bank stock

SYDNEY, Jan 10, 2026, 17:16 AEDT — Market closed

National Australia Bank Ltd (ASX:NAB) shares ended 0.2% lower at A$41.02 on Friday, with ANZ down 0.6%, Westpac off 0.3% and Commonwealth Bank down 0.1% as financials weighed on the session. The benchmark S&P/ASX 200 closed down 3 points at 8,717.80. (Small Caps)

That matters because the big banks trade like rate proxies. When traders pull forward or push out a move by the Reserve Bank of Australia, it can hit expectations for net interest margin — the gap between what a bank earns on loans and pays on deposits and funding.

RBA officials have tried to keep the market from getting too relaxed. “Inflation above 3% — let’s be clear, it’s too high,” Deputy Governor Andrew Hauser said, after data showed November’s annual inflation cooled but stayed above the central bank’s 2%-3% target band. (Reuters)

The inflation read itself has been messy. Data showed headline CPI slowed to 3.4% year-on-year in November, while the trimmed mean — a core measure that strips out big one-off moves — eased to 3.2%, and Reuters reported investors still saw a 33% risk of a February hike. Harry Murphy Cruise, head of economic research at Oxford Economics Australia, called 3.2% “the magic number” for the trimmed mean in the late-January quarterly read. (Reuters)

The next test lands on Jan. 28, when the Australian Bureau of Statistics is due to release December CPI, alongside updates to the quarterly CPI tables. That print will shape how hard traders lean into the February rates call. (Australian Bureau of Statistics)

For NAB, the next marker is its first-quarter trading update on Feb. 18, with half-year results due May 4, according to the bank’s financial calendar. Investors typically use those updates to gauge loan growth, deposit pricing and costs, and whether bad-debt pressures are creeping in. (NAB)

Technically, NAB has slipped 2.77% so far in 2026 and sits just under its 50-day moving average of A$41.74. The stock is about 9% below its 52-week high of A$45.25 set on Nov. 6, 2025, and above the 52-week low of A$31.13. (Intelligent Investor)

But the new monthly inflation series can whip around, and banks can get hit from both sides: higher rates can lift margins but also strain borrowers. Any upside surprise in inflation, or a renewed fight for deposits, would make it harder for NAB to hold recent levels.

With the ASX shut over the weekend, attention turns to Monday’s reopen and whether bank sellers return early. The next hard dates are the RBA’s Feb. 2–3 meeting and NAB’s Feb. 18 trading update. (Gov)

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
AustralianSuper boosts Lynas Rare Earths stake — what it could signal for LYC stock before the next catalyst
Previous Story

AustralianSuper boosts Lynas Rare Earths stake — what it could signal for LYC stock before the next catalyst

Woolworths share price jumps 1.8%: why WOW.AX rose and what to watch next
Next Story

Woolworths share price jumps 1.8%: why WOW.AX rose and what to watch next

Go toTop